Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.

BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients...

詳細記述

書誌詳細
主要な著者: Jubb, A, Cesario, A, Ferguson, M, Congedo, M, Gatter, K, Lococo, F, Mulè, A, Pezzella, F
フォーマット: Journal article
言語:English
出版事項: 2011